Collegium Pharmaceutical Inc (COLL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $786.83M
Last updated: Nov 17, 2026 at 11:04 AM ET
Collegium Pharmaceutical Inc (COLL) Earnings: Report Dates and Results
Collegium Pharmaceutical (COLL) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Collegium Pharmaceutical reported EPS of $1.71, above the $1.53 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
COLL has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.7% above the $1.85 reported for the quarter ended Dec 31, 2025.
COLL Earnings Call
The latest COLL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, COLL beat 27 and missed 13. Revenue for the quarter ended Sep 30, 2026 was $216.34M, up 3.3% from $209.36M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.71 | $1.53 | N/A | +11.76% | Beat | -24.0% | 7 | 1 up, 2 down | Nov 5, 2026 | $216.34M |
| Jun 30, 2026 | $1.57 | $1.48 | N/A | +6.08% | Beat | +6.8% | 2 | 2 up, 3 down | Aug 6, 2026 | $199.88M |
| Mar 31, 2026 | $1.76 | $1.52 | $1.27 - $1.74 | +15.79% | Beat | +18.1% | 5 | 1 up, 2 down | May 7, 2026 | $193.52M |
| Dec 31, 2025 | $1.85 | $2.01 | $1.93 - $2.26 | -7.96% | Miss | +4.5% | 5 | 1 up, 0 down | Feb 26, 2026 | $205.45M |
| Sep 30, 2025 | $2.25 | $1.86 | $1.79 - $1.95 | +20.97% | Beat | +39.8% | 4 | 0 up, 2 down | Nov 6, 2025 | $209.36M |
| Jun 30, 2025 | $1.47 | $1.43 | N/A | +2.80% | Beat | -9.3% | 4 | 0 up, 1 down | Aug 7, 2025 | $188.00M |
| Mar 31, 2025 | $1.49 | $1.45 | $1.34 - $1.66 | +2.76% | Beat | +2.8% | 4 | 0 up, 0 down | May 8, 2025 | $177.76M |
| Dec 31, 2024 | $1.77 | $1.54 | $1.49 - $1.63 | +15.12% | Beat | +12.0% | 4 | 2 up, 0 down | Feb 27, 2025 | $181.95M |
| Sep 30, 2024 | $1.61 | $1.59 | $1.45 - $1.84 | +1.26% | Beat | +20.1% | 4 | 2 up, 0 down | Nov 7, 2024 | $159.30M |
| Jun 30, 2024 | $1.62 | $1.49 | $1.37 - $1.62 | +8.72% | Beat | +28.6% | 4 | 4 up, 0 down | Aug 8, 2024 | $145.28M |
| Mar 31, 2024 | $1.45 | $1.47 | N/A | -1.36% | Miss | +9.8% | 3 | 0 up, 1 down | May 9, 2024 | $144.92M |
| Dec 31, 2023 | $1.58 | $1.25 | N/A | +26.40% | Beat | N/A | 2 | 0 up, 1 down | Feb 22, 2024 | $149.75M |
| Sep 30, 2023 | $1.34 | $1.24 | N/A | +8.06% | Beat | +21.8% | 3 | 0 up, 1 down | Nov 7, 2023 | $136.71M |
| Jun 30, 2023 | $1.26 | $1.22 | N/A | +3.28% | Beat | +4.1% | 4 | 0 up, 1 down | Aug 3, 2023 | $135.55M |
| Mar 31, 2023 | $1.32 | $1.51 | N/A | -12.58% | Miss | +45.1% | 5 | 1 up, 0 down | May 4, 2023 | $144.77M |
| Dec 31, 2022 | -$0.21 | -$0.14 | -$0.80 - $0.30 | -50.00% | Miss | N/A | 4 | 4 up, 0 down | Feb 23, 2023 | $129.62M |
| Sep 30, 2022 | $1.10 | $1.38 | N/A | -20.29% | Miss | +41.0% | 4 | 0 up, 1 down | Nov 3, 2022 | $127.01M |
| Jun 30, 2022 | $1.21 | $1.44 | $1.08 - $1.97 | -15.97% | Miss | +49.4% | 7 | 0 up, 1 down | Aug 4, 2022 | $123.55M |
| Mar 31, 2022 | $0.91 | $0.90 | $0.44 - $1.04 | +1.11% | Beat | -5.2% | 6 | 0 up, 0 down | May 10, 2022 | $83.75M |
| Dec 31, 2021 | -$0.51 | $1.04 | $0.96 - $1.11 | -149.04% | Miss | -355.0% | 7 | 1 up, 1 down | Feb 24, 2022 | $27.36M |
| Sep 30, 2021 | $0.78 | $0.96 | $0.90 - $1.03 | -18.75% | Miss | -24.3% | 6 | N/A | Nov 4, 2021 | $78.84M |
| Jun 30, 2021 | $0.81 | $0.95 | N/A | -14.74% | Miss | -14.7% | 4 | N/A | Aug 5, 2021 | $82.94M |
| Mar 31, 2021 | $0.96 | $1.00 | N/A | -4.00% | Miss | +9500.0% | 4 | N/A | May 6, 2021 | $87.72M |
| Dec 31, 2020 | $0.20 | $0.39 | N/A | -48.72% | Miss | +25.0% | 5 | N/A | Feb 25, 2021 | $76.27M |
| Sep 30, 2020 | $1.03 | $0.90 | N/A | +14.44% | Beat | +1960.0% | 5 | N/A | Nov 5, 2020 | $79.18M |
| Jun 30, 2020 | $0.95 | $0.86 | N/A | +10.47% | Beat | +955.6% | 5 | N/A | Aug 5, 2020 | $78.06M |
| Mar 31, 2020 | $0.01 | $0.41 | $0.08 - $0.64 | -97.56% | Miss | N/A | 6 | N/A | May 7, 2020 | $76.51M |
| Dec 31, 2019 | $0.16 | $0.10 | -$0.25 - $0.22 | +60.00% | Beat | -40.7% | 6 | N/A | Feb 27, 2020 | $74.20M |
| Sep 30, 2019 | $0.05 | $0.03 | N/A | +66.67% | Beat | N/A | 6 | N/A | Nov 6, 2019 | $72.94M |
| Jun 30, 2019 | $0.09 | -$0.04 | N/A | +325.00% | Beat | N/A | 6 | N/A | Aug 7, 2019 | $75.04M |
| Mar 31, 2019 | -$0.05 | -$0.15 | -$0.40 - -$0.12 | +66.67% | Beat | N/A | 5 | N/A | May 8, 2019 | $74.52M |
| Dec 31, 2018 | $0.27 | -$0.35 | -$0.50 - -$0.23 | +177.14% | Beat | N/A | 5 | N/A | Feb 27, 2019 | $73.43M |
| Sep 30, 2018 | -$0.25 | -$0.12 | N/A | -108.33% | Miss | N/A | 5 | N/A | Nov 8, 2018 | $70.18M |
| Jun 30, 2018 | -$0.15 | -$0.33 | -$0.67 - -$0.31 | +54.55% | Beat | N/A | 6 | N/A | Aug 8, 2018 | $73.06M |
| Mar 31, 2018 | -$0.57 | -$0.65 | -$0.73 - -$0.23 | +12.31% | Beat | N/A | 5 | N/A | May 9, 2018 | $63.75M |
| Dec 31, 2017 | -$0.54 | -$0.57 | -$0.67 - -$0.49 | +5.26% | Beat | N/A | 6 | N/A | Mar 7, 2018 | $10.79M |
| Sep 30, 2017 | -$0.45 | -$0.73 | -$0.80 - -$0.67 | +38.36% | Beat | N/A | 6 | N/A | Nov 8, 2017 | $11.95M |
| Jun 30, 2017 | -$0.72 | -$0.80 | -$0.85 - -$0.76 | +10.00% | Beat | N/A | 5 | N/A | Aug 9, 2017 | $3.56M |
| Mar 31, 2017 | -$0.79 | -$1.00 | N/A | +21.00% | Beat | N/A | N/A | N/A | May 10, 2017 | $2.17M |
| Dec 31, 2016 | -$1.02 | -$1.07 | N/A | +4.67% | Beat | N/A | N/A | N/A | Mar 9, 2017 | $1.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $7.06, up 9.5% from the year before. It was -$3.88 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $7.06 | +9.5% |
| Dec 31, 2024 | $6.45 | +17.3% |
| Dec 31, 2023 | $5.50 | +82.7% |
| Dec 31, 2022 | $3.01 | +47.5% |
| Dec 31, 2021 | $2.04 | -6.8% |
| Dec 31, 2020 | $2.19 | +776.0% |
| Dec 31, 2019 | $0.25 | N/A |
| Dec 31, 2018 | -$0.70 | N/A |
| Dec 31, 2017 | -$2.50 | N/A |
| Dec 31, 2016 | -$3.88 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,017 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,365 | 8 | |
| 2026Q1 | Mar 31, 2026 | 5,814 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,434 | 8 | |
| 2025Q3 | Sep 30, 2025 | 4,570 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,603 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,898 | 8 | |
| 2024Q4 | Dec 31, 2024 | 4,719 | 7 |
2026Q3 Earnings Call
Opening remarks
Ian Karp Head of Investor Relations Thank you. You may begin. Great. Thanks, Maria, and welcome to Collegium Pharmaceutical's Third Quarter 2026 Earnings Conference Call. I am joined today by Vikram Karnani, our President and Chief Executive Officer, and Colleen Tupper, our Chief Financial Officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 2000. We are cautioned that such forward-looking statements involve risks and uncertainties, detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website. And with that, I will now turn the call over to our President and CEO, Vikram Karnani.
Vikram Karnani President and CEO Thank you, Ian. Good morning, everyone, and thank you for joining our third quarter 2026 earnings call. Collegium is a dynamic commercial-stage biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions. Our success is built upon our proven ability to acquire, integrate, and grow differentiated medicines while creating long-term shareholder value. This strategy has established a portfolio of six differentiated medicines, reflecting the significant evolution our company has undertaken over the past several years. ADHD has become our lead growth driver, accounting for more than 36% of total revenue, up from just 19% last year. With Jornay PM and Azstarys, we have two complementary medicines supported by an expanding commercial platform to drive future growth. Meanwhile, our pain portfolio continues to generate robust cash flows, providing the financial flexibility to invest in our ADHD portfolio and further diversify our business. The team at Collegium remains focused, invigorated, and committed to making a meaningful difference in the lives of patients and creating long-term value for our shareholders. We delivered record quarterly net revenue of $216.3 million, up 3% year over year, driven by growth in ADHD during the important back-to-school season. Key achievements this quarter included Jornay PM prescriptions growing by 16%, generating a record $59.5 million in net revenue, up 24% year over year. Jornay PM prescribers also reached another all-time high, with nearly 33,000 healthcare providers writing Jornay PM prescriptions in the quarter, up 19% over Q3 of last year. Our investments in Jornay PM are translating into broader prescriber and continued prescription growth. Azstarys generated $26.5 million in net revenue during its first full quarter under our ownership.
Frequently Asked Questions About COLL
When is Collegium Pharmaceutical's next earnings date?
Collegium Pharmaceutical's next earnings report is expected for Feb 24, 2027.
Did COLL beat earnings estimates last quarter?
Yes. Collegium Pharmaceutical reported EPS of $1.71 for the quarter ended Sep 30, 2026, above the $1.53 estimate, a 11.76% surprise.
What EPS do analysts expect from COLL next quarter?
The consensus EPS estimate for Collegium Pharmaceutical for the quarter ending Dec 31, 2026 is $2.03 from 10 analysts, with estimates from $1.86 to $2.15.
How often does COLL beat earnings estimates?
Collegium Pharmaceutical beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.42%.
COLL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors